Javan Esfandiari - 11 Mar 2022 Form 4 Insider Report for CHEMBIO DIAGNOSTICS, INC.

Role
Executive Vice President, Chief Science and Technology Officer
Signature
/s/ Mark L. Johnson, Attorney-in-Fact for Javan Esfandiari
Issuer symbol
N/A
Transactions as of
11 Mar 2022
Net transactions value
$0
Form type
4
Filing time
15 Mar 2022, 21:30:25 UTC
Previous filing
01 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CEMI Restricted Stock Units Award $0 +144,000 $0.000000 144,000 11 Mar 2021 Common Stock 144,000 Direct F1, F2
transaction CEMI Incentive Stock Options Award $0 +69,435 $0.000000 69,435 11 Mar 2021 Common Stock 69,435 $1.25 Direct F3
transaction CEMI Nonqualified Stock Options Award $0 +208,279 +10413950% $0.000000 208,281 11 Mar 2021 Common Stock 208,281 $1.25 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 On March 16, 2020, the reporting person was granted 144,000 restricted stock units scheduled to vest in equal installments on March 11 of each of 2023, 2024 and 2025, subject to continued service through each vesting date.
F3 The incentive stock options are scheduled to vest and become exercisable over four years, with two shares vesting on March 11, 2023, two shares vesting on March 11, 2024, two shares vesting on March 11, 2025 and the remaining 69,429 shares vesting on March 11, 2026, subject to continued service through each vesting date.
F4 The nonqualified stock options are scheduled to vest and become exercisable over three years, with 69,426 shares vesting on March 11, 2023, 69,427 shares vesting on March 11, 2024, and 69,426 shares vesting on March 11, 2025, subject to continued service through each vesting date.

Remarks:

Executive Vice President, Chief Science and Technology Officer